Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Maziarz, Richard T., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, Tam, Constantine S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2020
Schlagworte:
Immunobiology and Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042998/
https://ncbi.nlm.nih.gov/pubmed/32074277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001026
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge